BIX 01294

For research use only. Not for use in humans.

目录号：S8006

CAS No. 1392399-03-9

BIX01294 是一种G9a histone methyltransferase抑制剂，无细胞试验中IC50为2.7 μM，降低大部分组蛋白H3K9me2，也微弱抑制GLP（主要是H3K9me3），对其他组蛋白甲基转移酶没有显著的抑制活性。BIX01294 可诱导自噬。BIX01294 还可通过癌蛋白 NSD1、NSD2 和 NSD3 来抑制H3K36甲基化。

规格

价格

库存

购买数量

10mM (1mL in DMSO)	RMB 1566.17	现货
10mg	RMB 1222.94	现货
50mg	RMB 3415.23	现货
大包装	有超大折扣

大剂量询单有大折扣!

今日订购，明日送达，全国免运费！

全国免费电话：400-668-6834 | Email：info@selleck.cn

客户使用Selleck生产的BIX 01294发表文献26篇：

Cancer Cell, 2019, 35(5):752-766

PubMed: 31085176 ( click the link to review the publication )

Cancer Gene Ther, 2021, 10.1038/s41417-021-00335-3

PubMed: 33888871 ( click the link to review the publication )

Biochem J, 2021, BCJ20200314

PubMed: 33410908 ( click the link to review the publication )

Nat Commun, 2020, 11(1):604

PubMed: 32001678 ( click the link to review the publication )

Oxid Med Cell Longev, 2020, 12;2020:6983268

PubMed: 32256958 ( click the link to review the publication )

Cancer Sci, 2020, 112(1):133-143

PubMed: 33067904 ( click the link to review the publication )

Sci Rep, 2020, 10(1):377

PubMed: 31941995 ( click the link to review the publication )

Front Genet, 2020, 11:43

PubMed: 32117455 ( click the link to review the publication )

Int J Biol Sci, 2020, 16(7):1252-1263

PubMed: 32174799 ( click the link to review the publication )

J Cell Physiol, 2020, 10.1002/jcp.29970

PubMed: 32700783 ( click the link to review the publication )

Cell Rep, 2019, 28(2):512-525.e6

PubMed: 31291585 ( click the link to review the publication )

Cell Death Dis, 2019, 10(12):877

PubMed: 31754093 ( click the link to review the publication )

Biochim Biophys Acta Gene Regul Mech, 2019, 1862(2):173-183

PubMed: 30716533 ( click the link to review the publication )

Cancer Sci, 2019, 110(11):3442-3452

PubMed: 31432592 ( click the link to review the publication )

Sci Rep, 2019, 9(1):1897

PubMed: 30760778 ( click the link to review the publication )

Cell Adh Migr, 2019, 13(1):285-292

PubMed: 31271097 ( click the link to review the publication )

Sci Adv, 2019, 5(3):eaau7566

PubMed: 30854428 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(5):2349-2364

PubMed: 30649550 ( click the link to review the publication )

Nucleic Acids Res, 2019, 47(21):10977-10993

PubMed: 31612207 ( click the link to review the publication )

Cancer Res, 2018, 78(20):5731-5740

PubMed: 30135193 ( click the link to review the publication )

Cell Death Dis, 2018, 9(3):278

PubMed: 29449539 ( click the link to review the publication )

J Pineal Res, 2018, 65(2):e12497

PubMed: 29655234 ( click the link to review the publication )

Hum Pathol, 2018, 72:117-126

PubMed: 29133140 ( click the link to review the publication )

Oncotarget, 2016, 7(28):43162-43176

PubMed: 27281610 ( click the link to review the publication )
Cancer Res, 2015, 75(11):2375-86

PubMed: 25840984 ( click the link to review the publication )

PLoS One, 2015, 10(9):e0138390

PubMed: 26397365 ( click the link to review the publication )

产品安全说明书

Histone Methyltransferase抑制剂选择性比较

生物活性

产品描述

BIX01294 是一种G9a histone methyltransferase抑制剂，无细胞试验中IC50为2.7 μM，降低大部分组蛋白H3K9me2，也微弱抑制GLP（主要是H3K9me3），对其他组蛋白甲基转移酶没有显著的抑制活性。BIX01294 可诱导自噬。BIX01294 还可通过癌蛋白 NSD1、NSD2 和 NSD3 来抑制H3K36甲基化。

靶点

G9a ^[1]
(Cell-free assay)

2.7 μM

体外研究

BIX01294是选择性的G9a组蛋白甲基转移酶抑制剂，在实验浓度范围内不影响SUV39H1(H320R)和PRMT1。BIX-01294特异性抑制G9a (H3K9me2)，并在较小程度上抑制密切相关的GLP酶（主要是H3K9me3），作用于G9a 和GLP，IC50分别为1.7 μM 和 38 μM。BIX-01294抑制G9a，与SAM按非竞争性的方式。BIX-01294 (4.1μM) 作用于野生型ES细胞，小鼠胚胎成纤维细胞和HeLa细胞，而非缺乏G9a的干细胞，降低H3K9me2水平。BIX-01294是抑制有价值的染色体H3K9me2瞬态调制的抑制剂。BIX-01294在一些G9a靶向基因上，包括Bim1 和Serac1，降低H3K9me2。^[1]BIX01294可使HIV-1病毒从潜伏感染的细胞，如ACH-2和 OM10.1中重新表达。^[2]

Cell Data

Cell Lines	Assay Type	Concentration	Incubation Time	Activity Description	PMID
HeLa cells	MlW3SpVv[3Srb36gZZN{[Xl?			NYqxe5RCUW6qaXLpeIlwdiCxZjDFVms2KHCqb4PwbI9zgWyjdHnvckBqdiC\|b4LibZRwdC2\|dHnteYxifGWmIHj1cYFvKEinTHGgZ4VtdHNuIFnDOVA:OC5yNUmg{txO	NVTBPI1jRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkO2OVY1ODdpPkKzOlU3PDB5PD;hQi=>
HeLa	M4LLUWZ2dmO2aX;uJIF{e2G7		M3T3R\|QvPSCqcoO=	NV2zU3I5UW6qaXLpeIlwdiCxZjDFZo9t[X[rcoXzJIdtgWOxcILveIVqdi:vYYTybZgheHKxdHXpckBXWDRyIHXueJJ6KGmwIHj1cYFvKEinTHGgZ4VtdHNiYX\0[ZIhPC53IHjyd{Bj\XSjLXzhZ5RidWG\|ZTDy[ZBwenSncjDhd5NigSxiSVO1NEA:KDBwOU[2JO69VS5?	M3TxelxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NkK0N\|g4Lz5{OU[yOFM5PzxxYU6=
BL21 (DE3)-Gold	MoXNSpVv[3Srb36gZZN{[Xl?		MXKyNEBucW6\|	MVvJcohq[mm2aX;uJI9nKE5vdHXycYlv[WxiaHX4ZYhqe3SrZHnu[U11[WepZXSgbJVu[W5iR{nhJEg6OTNidH:gNVE6OyC{ZYPp[JVmeyliZYjwdoV{e2WmIHnuJGV{[2incnnjbIliKGOxbHmgRmwzOSBqRFWzLU1Id2ymIHPlcIx{KHW\|aX7nJIhqe3SxbnWgTFMhMDFidH:gNVUhemW\|aXT1[ZMqKGG\|IIP1ZpN1emG2ZTDwdoVqdmO3YnH0[YQh\m:{IEKwJI1qdnNiZn;scI94\WRiYomgd5Vje3S{YYTlJIFl\Gm2aX;uJIJ6KG2jc4Ogd5Bm[3S{b33leJItKEmFNUCgQUAyNjlizszNMi=>	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzd{MEW1O{c,Ojd5MkC1OVc9N2F-
HL60	Ml20RY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NYX1fmp5PDhiaILz	MnuzRY51cXC{b3zp[oVz[XSrdnWgZYN1cX[rdImgZYdicW6\|dDDoeY1idiCKTE[wJINmdGy\|IHHmeIVzKDR6IHjyd{BjgSCFQ1u4JIF{e2G7LDDJR\|UxKD1iMj6yJO69VS5?	MYG8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN7M{m0PEc,Ojd\|OUO5OFg9N2F-
A549	MYPBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MWK0PEBpenN?	M{nNT2FvfGmycn;sbYZmemG2aY\lJIFkfGm4aYT5JIFo[Wmwc4SgbJVu[W5iQUW0PUBk\WyuczDh[pRmeiB2ODDodpMh[nliQ1PLPEBie3OjeTygTWM2OCB;IEKuPEDPxE1w	MljtQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjd\|OUO5OFgoRjJ5M{mzPVQ5RC:jPh?=
HepG2	MVLBcpRqeHKxbHnm[ZJifGm4ZTDhd5NigQ>?		MUO0PEBpenN?	NI\Yd3NCdnSrcILvcIln\XKjdHn2[UBi[3Srdnn0fUBi\2GrboP0JIh2dWGwIFjldGczKGOnbHzzJIFnfGW{IES4JIhzeyCkeTDDR2s5KGG\|c3H5MEBKSzVyIE2gN{44KM7:TT6=	NV3BfXZJRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkezPVM6PDhpPkK3N\|k{QTR6PD;hQi=>
K562	MmjiRY51cXC{b3zp[oVz[XSrdnWgZZN{[Xl?		NH;ySmk1QCCqcoO=	MULBcpRqeHKxbHnm[ZJifGm4ZTDhZ5Rqfmm2eTDh[4FqdnO2IHj1cYFvKEt3NkKgZ4VtdHNiYX\0[ZIhPDhiaILzJIJ6KEOFS{igZZN{[XluIFnDOVAhRSB\|Lkmg{txONg>?	NFWxXHA9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{N{O5N\|k1QCd-MkezPVM6PDh:L3G+
MDA-MB-231	MXLGeY5kfGmxbjDhd5NigQ>?		MkTJNkBl[Xm\|	MV3Jcohq[mm2aX;uJI9nKEd7YTDpckBpfW2jbjDNSGEuVUJvMkOxJINmdGy\|IHHzd4V{e2WmIHHzJJJm\HWldHnvckBqdiCKM1u5cYUzKGyndnXsJIFnfGW{IEKg[IF6eyCkeTDpcY12dm:obIXvdoV{[2WwY3WgbY4u[2WubDD3[ZN1\XKwIHHuZYx6e2m\|LDDJR\|UxKD1iND61OlMh\|ryPLh?=	MYW8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTV2MUO1N{c,Ojl3NEGzOVM9N2F-
K562	NHrkOmRHfW6ldHnvckBie3OjeR?=	MViwMlUhfG9iMjD1US=>	NGPoNWM4OiCqcoO=	NUHCWphJUW6qaXLpeIlwdiCxZjDobZN1d26nIH3leIh6dHS{YX7z[oVz[XOnIFe5ZUBqdiCqdX3hckBMPTZ{IHPlcIx{KGG\|c3Xzd4VlKGG\|IILl[JVkfGmxbjDpckBpcXO2b37lJGg{UzmvZUKgcIV3\Wy\|IHH0JFAvPSC2bzCyJJVOKGGodHXyJFczKGi{czDifUBY\XO2ZYLuJIJtd3RiYX7hcJl{cXN?	MV28ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zPzN7M{m0PEc,Ojd\|OUO5OFg9N2F-
TC32	NGftTWpyUFSVIHHzd4F6			MlLGdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFSFM{KgZ4VtdHN?	NGrpZW49[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
DAOY	MXXxTHRUKGG\|c3H5			MWHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhTEGRWTDj[Yxtew>?	M1PnNFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	MoG5dWhVWyCjc4PhfS=>			MnrZdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFOMLVfCUVIh[2WubIO=	NXLCPG11RGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
A673	MUjxTHRUKGG\|c3H5			Mny3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEF4N{OgZ4VtdHN?	M170bFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SK-N-MC	NF76PVByUFSVIHHzd4F6			M1u1c5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVSz3OMW1EKGOnbHzz	M1XB[VxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
BT-37	NF3YZ\|RyUFSVIHHzd4F6			NHXKW5dyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiQmStN\|ch[2WubIO=	NHL0OFE9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB-EBc1	M1HGVJFJXFNiYYPzZZk>			MYnxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5IhVkJvRVLjNUBk\Wyucx?=	M1\zVVxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Saos-2	MY\xTHRUKGG\|c3H5			M4f4VpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCVYX;zMVIh[2WubIO=	MX68ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-SH	Ml7OdWhVWyCjc4PhfS=>			MnTTdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKFONLV6tV2gh[2WubIO=	NGS1Wmo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
NB1643	NWK1OpNneUiWUzDhd5NigQ>?			NF:3eFlyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiTlKxOlQ{KGOnbHzz	NG\5fnU9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
LAN-5	M3zBfZFJXFNiYYPzZZk>			MkfEdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKEyDTj21JINmdGy\|	NEDQfJo9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
BT-12	MYPxTHRUKGG\|c3H5			NVnt[ZNveUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IFLUMVEzKGOnbHzz	NHrHT5M9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
Rh18	NGj1PWdyUFSVIHHzd4F6			M3nEe5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaEG4JINmdGy\|	MVq8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
OHS-50	Mk[zdWhVWyCjc4PhfS=>			NX3RWWhleUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiUILpcYFzgSC\|Y4Ll[Y4h\m:{IF;IV{02OCClZXzsdy=>	NVfmNohvRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
RD	M2HDUpFJXFNiYYPzZZk>			NEWzNGpyUFSVIH;mJJBm\GmjdILpZ{Bk[W6lZYKgZ4VtdCCuaX7ld{B1dyCrZHXueIlngSCvdXz0bZBt\SCxcIDvdpR2dmm2aXXzJIZweiCmcoXnJJJmeHW{cH;zbY5oQiCScnntZZJ6KHOlcnXlckBnd3JiUlSgZ4VtdHN?	NX[5WVNyRGFidHHy[4V1RSehYnzhcosoKGi{ZX[9K4h1fHC\|Oj:vdJVjdWWmLn7jZokvdmyvLn7pbE5od3ZxMkm0N\|UyOzlpPkK5OFM2OTN7PD;hQi=>
MG 63 (6-TG R)	NWXEWG1oeUiWUzDhd5NigQ>?			MoX3dWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohWHKrbXHyfUB{[3KnZX6g[o9zKE2JIE[zJEg3NVSJIGKpJINmdGy\|	MlqwQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
wild type fibroblast cells	NETBOJdyUFSVIHHzd4F6			MYjxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBRemmvYYL5JJNkemWnbjDmc5Ih[2:wdILvcEBJcCC5aXzkJJR6eGViZnnido9jdGG\|dDDj[Yxtew>?	M1;TXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	NYfmWWtKeUiWUzDhd5NigQ>?			M1zW[5FJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KFC{aX3hdpkhe2O{ZXXuJIZweiCUaESxJINmdGy\|	MkXJQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
NB1643	NYfwS\|U2eUiWUzDhd5NigQ>?			MkLEdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgUmIyPjR\|IHPlcIx{	NInuc5Q9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
A673	M2LMUpFJXFNiYYPzZZk>			Mn3PdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgRVY4OyClZXzsd{k>	MX[8ZUB1[XKpZYS9K39jdGGwazegbJJm\j1paIT0dJM7Ny:ydXLt[YQvdmOkaT7ucI0vdmmqLnfvek8zQTR\|NUGzPUc,Ojl2M{WxN\|k9N2F-
SK-N-MC	NFvDOnFyUFSVIHHzd4F6			MmfWdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgV2suVi2PQzDj[Yxtew>?	M1TtVFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
SJ-GBM2	NIDuTpVyUFSVIHHzd4F6			NXfXU\|VOeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhW0pvR1LNNkBk\Wyucx?=	MnXKQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
BT-37	MULxTHRUKGG\|c3H5			NWflUYJVeUiWUzDv[kBx\WSrYYTybYMh[2GwY3XyJINmdGxibHnu[ZMhfG9iaXTlcpRq\nlibYXseIlxdGVib4Dwc5J1fW6rdHnld{Bnd3JiZIL1[{Bz\XC3coDvd4lv\zpiQ3;u[olzdWG2b4L5JJNkemWnbjDmc5IhSlRvM{egZ4VtdHN?	NHXzeXY9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
TC32	M3\5c5FJXFNiYYPzZZk>			M1\BSpFJXFNib3[gdIVlcWG2cnnjJINidmOncjDj[YxtKGyrbnXzJJRwKGmmZX70bYZ6KG23bITpdIxmKG:ycH;yeJVvcXSrZYOg[o9zKGS{dXegdoVxfXKyb4Ppcoc7KEOxbn\pdo1ifG:{eTDzZ5Jm\W5iZn;yJHREOzJiY3XscJM>	M4rCPFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh41	NIXBZ3pyUFSVIHHzd4F6			Mm\UdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVog1OSClZXzsdy=>	MlLIQIEhfGG{Z3X0QUdg[myjbnunJIhz\WZ;J3j0eJB{Qi9xcIXicYVlNm6lYnmucoxuNm6raD7nc5YwOjl2M{WxN\|koRjJ7NEO1NVM6RC:jPh?=
RD	MV7xTHRUKGG\|c3H5			MmjEdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgVmQh[2WubIO=	M3nSXFxiKHSjcnfleF0oZ2KuYX7rK{BpemWoPTfoeJRxezpxL4D1Zo1m\C6wY3LpMo5tdS6waXiu[493NzJ7NEO1NVM6Lz5{OUSzOVE{QTxxYU6=
Rh30	NXv1TJpreUiWUzDhd5NigQ>?			MYHxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDSbFMxKGOnbHzz	NFLsZVk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
OHS-50	NHzhSpVyUFSVIHHzd4F6			MoXmdWhVWyCxZjDw[YRq[XS{aXOgZ4Fv[2W{IHPlcIwhdGmwZYOgeI8hcWSnboTp[pkhdXWudHnwcIUhd3Cyb4L0eY5qfGmnczDmc5Ih\HK3ZzDy[ZB2enCxc3nu[\|ohS2:wZnnycYF1d3K7IIPjdoVmdiCob4KgU2hUNTVyIHPlcIx{	NIjGcXk9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+
SK-N-SH	MkLDdWhVWyCjc4PhfS=>			MYLxTHRUKG:oIIDl[IlifHKrYzDjZY5k\XJiY3XscEBtcW6nczD0c{Bq\GWwdHnmfUBufWy2aYDs[UBweHCxcoT1col1cWW\|IH\vdkBlenWpIILldJVzeG:\|aX7nPkBEd26oaYLtZZRwenlic3Py[YVvKG[xcjDTT{1PNVOKIHPlcIx{	NHXFT4I9[SC2YYLn[ZQ:L1:kbHHub{chcHKnZk2nbJR1eHN8Lz;weYJu\WRwbnPibU5vdG1wbnnoModwfi9{OUSzOVE{QSd-Mkm0N\|UyOzl:L3G+

... Click to View More Cell Line Experimental Data

Assay

Methods	Test Index	PMID
Western blot	Cyclin D1 / CDK2 / CDK4 / CDK 6 / Cyclin E ; PubMed: 25198515 PLoS One Western blot analysis of cyclins and CDKs associated with G1 phase in neuroblastoma cells treated with BIX01294 or water for 2 days. α-Tubulin levels are shown as the loading control. G9a / H3K9me2 ; PubMed: 25198515 PLoS One Western blot analysis of G9a function in neuroblastoma cells treated with BIX01294 or water for 2 days. Atg7 / Atg5 / Atg5-Atg12 / Atg3 / Atg12 / LC3B ; PubMed: 25198515 PLoS One Western blot analysis of autophagy-related genes in neuroblastoma cells treated with BIX01294 or water for 2 days. α-Tubulin levels are shown as the loading control.	25198515
Immunofluorescence	Ran / H3K9me3 ; PubMed: 30565836 Aging Cell Effects of histone methyltransferase G9a inhibitors on the Ran gradient and H3K9me3 levels in human fibroblasts. Chemical inhibitors (Bix01294, UNC0638, A‐366) were applied to human fibroblasts and endogenous Ran and Histone H3K9me3 levels examined by IF microscopy. Scale bar 20 μm.	30565836
Growth inhibition assay	Cell viability; PubMed: 26013382 Mol Cells HepG2 cells were treated with different concentrations of BIX01294. After 24 h, cell viability was measured by the MTT assay.	26013382

参考文献

溶解度 (25°C)

体外	DMSO	98 mg/mL (163.32 mM)
	Water	98 mg/mL (163.32 mM)
	Ethanol	'8 mg/mL

* 溶解度检测是由Selleck技术部门检测的，可能会和文献中提供的溶解度有所差异，这是由于生产工艺和批次不同产生的正常现象。请按照顺序依次加入各个纯溶剂。

化学数据 Download BIX 01294 SDF

分子量	600.02
化学式	C₂₈H₃₈N₆O₂.3HCl
CAS号	1392399-03-9
储存条件	3年-20°C 粉状 2年-80°C 溶于溶剂
别名	N/A

动物体内配方计算器 (澄清溶液)

第一步：请输入基本实验信息（考虑到实验过程中的损耗，建议多配一只动物的药量）

给药剂量

mg/kg

动物平均体重

g

每只动物给药体积

ul

动物数量

只

第二步：请输入动物体内配方组成（配方适用于不溶于水的药物；不同批次药物配方比例不同，请联系Selleck为您提供正确的澄清溶液配方）

% DMSO+ % + % Tween 80+ % ddH₂O

计算重置

计算结果:

工作液浓度： mg/ml；

DMSO母液配制方法： mg 药物溶于 μL DMSO溶液（母液浓度 mg/mL，注：如该浓度超过该批次药物DMSO溶解度，请先联系Selleck）；

体内配方配制方法：取 μL DMSO母液，加入 μL PEG300，混匀澄清后加入μL Tween 80，混匀澄清后加入 μL ddH₂O，混匀澄清。

注意：1. 首先保证母液是澄清的；
2. 一定要按照顺序依次将溶剂加入，进行下一步操作之前必须保证上一步操作得到的是澄清的溶液，可采用涡旋、超声或水浴加热等物理方法助溶。

计算器

摩尔浓度计算器

本计算器可帮助您计算出特定溶液中溶质的质量、溶液浓度和体积之间的关系，公式为:

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

质量

浓度

体积

分子量
=

×

×

*在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。

稀释计算器

用本工具协助配置特定浓度的溶液，使用的计算公式为：

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

稀释公式一般简略地表示为: C1V1 = C2V2 ( 输入输出 )

C1

V1

C2

V2
×

=

×

在配置溶液时，请务必参考Selleck产品标签上、MSDS / COA（可在Selleck的产品页面获得）批次特异的分子量使用本工具。.

连续稀释计算器方程

连续稀释
初始浓度:
稀释倍数:

计算结果

C1=C0/X	C1:	LOG(C1):
C2=C1/X	C2:	LOG(C2):
C3=C2/X	C3:	LOG(C3):
C4=C3/X	C4:	LOG(C4):
C5=C4/X	C5:	LOG(C5):
C6=C5/X	C6:	LOG(C6):
C7=C6/X	C7:	LOG(C7):
C8=C7/X	C8:	LOG(C8):

分子量计算器

通过输入化合物的化学式来计算其分子量：

注：化学分子式大小写敏感。C10H16N2O2 c10h16n2o2

摩尔浓度计算器

质量	浓度	体积	分子量
=	×	×
计算

研究领域

产品类型

定制您的化合物库

BIX 01294

客户使用Selleck生产的BIX 01294发表文献26篇：

产品安全说明书

Histone Methyltransferase抑制剂选择性比较

生物活性

推荐的实验操作(此推荐来自于公开的文献所以Selleck并不保证其有效性)

参考文献

溶解度 (25°C)

化学数据 Download BIX 01294 SDF

动物体内配方计算器 (澄清溶液)

计算器

摩尔浓度计算器

质量 (mg) = 浓度 (mM) x 体积 (mL) x 分子量 (g/mol)

摩尔浓度计算公式

稀释计算器

开始浓度 x 开始体积 = 最终浓度 x 最终体积

稀释公式

连续稀释计算器方程

连续稀释

计算结果

分子量计算器

总分子量：g/mol

摩尔浓度计算器

技术支持

Histone Methyltransferase Signaling Pathway Map